Abstract

An article from the "Canada Communicable Disease Report" (CCDR), Volume 36 • ACS-14, November 2010. The purpose of this document is to apply the Erickson, De Wals and Farand framework on immunization programs to review the following: the disease burden attributed to rotavirus; and the vaccine characteristics of Rotateq™. The rotavirus vaccine, Rotateq™, was approved for use in Canada on August 1, 2006. Source: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-14/pdf/acs-dcc-14-eng.pdf

Americas Canada epidemiology health policy Rotavirus